Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
719,8 EUR | +2,07 % | -0,24 % | +36,71 % |
Kurzporträt
- Endokrinologie (57,7%): Produkte zur Behandlung von Osteoporose, Diabetes und Wachstumsstörungen;
- Onkologie (19,5%);
- Immunologische Erkrankungen (11,1%);
- Neurologie (8,4%): hauptsächlich Medikamente zur Behandlung von Depressionen und Schizophrenie;
- Sonstige (3,3%).
Der Nettoumsatz verteilt sich geografisch wie folgt: Vereinigte Staaten (63,9%), Europa (18,1%), Japan (4,9%), China (4,5%) und Sonstige (8,6%).
Mitarbeiterzahl: 43 000
Umsatz nach Geschäftsbereich
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Human Pharmaceutical Products
100,0
%
| 28 541 | 100,0 % | 34 124 | 100,0 % | +19,56 % |
Umsatz je Region
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
63,9
%
| 18 190 | 63,7 % | 21 791 | 63,9 % | +19,80 % |
Europe
18,1
%
| 4 299 | 15,1 % | 6 175 | 18,1 % | +43,62 % |
Other Foreign Countries
8,6
%
| 2 852 | 10,0 % | 2 946 | 8,6 % | +3,30 % |
Japan
4,9
%
| 1 747 | 6,1 % | 1 673 | 4,9 % | -4,28 % |
China
4,5
%
| 1 453 | 5,1 % | 1 540 | 4,5 % | +5,98 % |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 01.01.96 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 01.01.01 |
Ruth Gimeno
PSD | President | - | - |
Diogo Rau
CTO | Chief Tech/Sci/R&D Officer | - | 17.05.21 |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 16.10.23 |
Alonzo Weems
CMP | Compliance Officer | - | 01.01.97 |
Chief Tech/Sci/R&D Officer | 50 | 01.01.18 | |
Corporate Officer/Principal | - | 01.01.05 | |
Ilya Yuffa
PRN | Corporate Officer/Principal | 49 | - |
Ronald DeMattos
PRN | Corporate Officer/Principal | - | - |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Director/Board Member | 63 | 25.01.21 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 01.04.09 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 01.01.05 |
Juan Luciano
BRD | Director/Board Member | 62 | 01.02.16 |
William Kaelin
BRD | Director/Board Member | 66 | 04.06.12 |
David Ricks
CEO | Chief Executive Officer | 56 | 01.01.96 |
Jamere Jackson
BRD | Director/Board Member | 54 | 01.10.16 |
Director/Board Member | 52 | 12.12.11 | |
Marschall Runge
BRD | Director/Board Member | 69 | 01.09.13 |
Karen Walker
BRD | Director/Board Member | 62 | 01.12.18 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 950 770 386 | 948 828 863 ( 99,80 %) | 365 000 ( 0,0384 %) | 99,80 % |
Unternehmensbesitz
Name | Aktien | % | Bewertung |
---|---|---|---|
8 084 411 | 6,83% | 50 293 848 $ | |
PROQR THERAPEUTICS N.V. 16,55% | 13 371 562 | 16,55% | 26 208 262 $ |
4 000 000 | 9,40% | 20 920 000 $ | |
21 776 804 | 7,60% | 11 332 213 $ | |
AC IMMUNE SA 3,64% | 3 615 328 | 3,64% | 8 279 101 $ |
125 405 | 1,81% | 1 218 937 $ |
Unternehmenskontakt
Konzerngesellschaften
Name | Kategorie und Branche |
---|---|
ELI Lilly & Company (India) Pvt Ltd.
ELI Lilly & Company (India) Pvt Ltd. Pharmaceuticals: MajorHealth Technology ELI Lilly & Company (India) Pvt Ltd. manufactures and markets pharmaceutical products. The firm's products treat diabetes, gastric cancer, lung cancer, osteoporosis, rheumatoid arthritis, men's health and growth-hormone deficiency. The company was founded in 1993 and is headquartered in Gurgaon, India. |
Pharmaceuticals: Major
|
Eli Lilly Services India Pvt Ltd.
Eli Lilly Services India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly Services India Pvt Ltd. is an Indian company that discovers, develops, manufactures and sells pharmaceutical products. The private company is based in Bangalore, India and was founded in 2015. |
Pharmaceuticals: Major
|
Eli Lilly Export SA (Switzerland)
Eli Lilly Export SA (Switzerland) Medical DistributorsDistribution Services Part of Eli Lilly & Co., Eli Lilly Export SA is a pharmaceutical company based in Vernier, Switzerland. The Swiss company combines care with research to develop innovative solutions for a better life worldwide. |
Medical Distributors
|
Kinsale Financial Services
| |
Lilly Nederland Finance BV
Lilly Nederland Finance BV Miscellaneous Commercial ServicesCommercial Services Part of Eli Lilly & Co., Lilly Nederland Finance BV leases non-financial intangible assets. The private company is based in Utrecht, Netherlands. |
Miscellaneous Commercial Services
|
Eli Lilly SA
Eli Lilly SA Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly SA is a Swiss company that manufactures medicines. The private company is based in Vernier, Switzerland. |
Pharmaceuticals: Major
|
Eli Lilly (Suisse) SA
| |
Lilly Global Nederland Holdings BV
Lilly Global Nederland Holdings BV Financial ConglomeratesFinance Part of Eli Lilly & Co., Lilly Global Nederland Holdings BV functions as an investment holding Dutch company. The private company is based in Utrecht, Netherlands. |
Financial Conglomerates
|
Eli Lilly Vostok SA
|
Sektor
Umsatz je Region
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+31,37 % | 595 Mrd. | |
-2,60 % | 367 Mrd. | |
+20,83 % | 334 Mrd. | |
+5,69 % | 289 Mrd. | |
+14,83 % | 239 Mrd. | |
+9,93 % | 211 Mrd. | |
-6,95 % | 203 Mrd. | |
+10,77 % | 171 Mrd. | |
+0,10 % | 163 Mrd. |
- Börse
- Aktien
- 858560 Aktie
- 858560 Aktie
- Unternehmen Eli Lilly and Company